Result of Annual General Meeting

RNS Number : 2572C

Microsaic Systems plc

17 June 2021

 

17 June 2021

Microsaic Systems plc

("Microsaic" or the "Company")

Result of Annual General Meeting

Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that all resolutions proposed at its Annual General Meeting held earlier today were duly passed on a poll, the results of which are set out below:

		Votes For*	% of votes cast	Votes against	% votes cast	Votes withheld
Ordinary Resolutions
1	To approve the audited accounts of the Company for the year ended 31 December 2020, together with the Directors' Report and Auditors' Report thereon	3,523,708,945	100.000	-	-	2,407,506
2	To re-appoint Saffery Champness LLP as auditors to the Company, and that the Board be authorised to fix the remuneration of the auditors	3,523,235,738	99.932	2,407,006	0.068	473,707
3	To re-appoint Gerard Brandon as a Director of the Company	3,526,086,451	99.999	30,000	0.001	-
4	To re-appoint Nigel Burton as a Director of the Company	3,526,086,451	99.999	30,000	0.001	-
5	To authorise the Directors to allot equity securities up to an aggregate nominal amount of £202,545	3,523,401,451	99.923	2,715,000	0.077	-
Special Resolutions
6	To disapply statutory pre-emption rights up to an aggregate nominal amount of £151,909	3,429,049,709	97.247	97,066,742	2.753	-
7	To adopt the new Articles of Association of the Company	3,526,086,451	99.999	30,000	0.001	-

* "Votes For" include votes giving the Chairman discretion.

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO - Bevan Metcalf, FD	[phone]
N+1 Singer (Nominated Adviser & Joint Broker)	[phone]
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
Turner Pope Investments (TPI) Limited (Broker) Andy Thacker / James Pope	[phone]

About Microsaic (www.microsaic.com)

Microsaic listed on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested £30m over the last 20 years before and after the IPO, Microsaic has a robust patent portfolio in cutting-edge technology purpose built for "Industry 4.0" which enables analytical detection and characterisation at the point-of-need, whether within a human health environment, conventional laboratory setting, or within a bioprocessing facility for continuous mass spectrometer detection and monitoring of data at any step in the process workflow.

 

END

 

 

RAGEANKXFSDFEEA